JP2014518266A - ジペプチジルペプチダーゼ−ｉｖ阻害剤の新規結晶形 - Google Patents

ジペプチジルペプチダーゼ−ｉｖ阻害剤の新規結晶形 Download PDF

Info

Publication number
JP2014518266A
JP2014518266A JP2014518879A JP2014518879A JP2014518266A JP 2014518266 A JP2014518266 A JP 2014518266A JP 2014518879 A JP2014518879 A JP 2014518879A JP 2014518879 A JP2014518879 A JP 2014518879A JP 2014518266 A JP2014518266 A JP 2014518266A
Authority
JP
Japan
Prior art keywords
difluorophenyl
crystalline
pyran
methylsulfonyl
dihydropyrrolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014518879A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518266A5 (enExample
Inventor
アローヨ，イツツイア
クルーガー，ダビダ
チエン，ピーン
モーメント，アーロン
ビフツ，テスフエイ
シーン，フエイ
ジヤーン，ヤンフェーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Merck Sharp & Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme LLC filed Critical Merck Sharp & Dohme LLC
Publication of JP2014518266A publication Critical patent/JP2014518266A/ja
Publication of JP2014518266A5 publication Critical patent/JP2014518266A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2014518879A 2011-06-29 2012-06-25 ジペプチジルペプチダーゼ−ｉｖ阻害剤の新規結晶形 Pending JP2014518266A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161502497P 2011-06-29 2011-06-29
US61/502,497 2011-06-29
PCT/US2012/043922 WO2013003249A1 (en) 2011-06-29 2012-06-25 Novel crystalline forms of a dipeptidyl peptidase-iv inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016198829A Division JP2017039752A (ja) 2011-06-29 2016-10-07 ジペプチジルペプチダーゼ−ｉｖ阻害剤の新規結晶形

Publications (2)

Publication Number Publication Date
JP2014518266A true JP2014518266A (ja) 2014-07-28
JP2014518266A5 JP2014518266A5 (enExample) 2015-05-21

Family

ID=47424494

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2014518879A Pending JP2014518266A (ja) 2011-06-29 2012-06-25 ジペプチジルペプチダーゼ−ｉｖ阻害剤の新規結晶形
JP2014518880A Active JP5873554B2 (ja) 2011-06-29 2012-06-25 キラルジペプチジルペプチダーゼ−ｉｖ阻害剤の調製プロセス
JP2016198829A Pending JP2017039752A (ja) 2011-06-29 2016-10-07 ジペプチジルペプチダーゼ−ｉｖ阻害剤の新規結晶形
JP2018055962A Withdrawn JP2018115191A (ja) 2011-06-29 2018-03-23 ジペプチジルペプチダーゼ−ｉｖ阻害剤の新規結晶形

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2014518880A Active JP5873554B2 (ja) 2011-06-29 2012-06-25 キラルジペプチジルペプチダーゼ−ｉｖ阻害剤の調製プロセス
JP2016198829A Pending JP2017039752A (ja) 2011-06-29 2016-10-07 ジペプチジルペプチダーゼ−ｉｖ阻害剤の新規結晶形
JP2018055962A Withdrawn JP2018115191A (ja) 2011-06-29 2018-03-23 ジペプチジルペプチダーゼ−ｉｖ阻害剤の新規結晶形

Country Status (12)

Country Link
US (4) US8895603B2 (enExample)
EP (2) EP2725905A4 (enExample)
JP (4) JP2014518266A (enExample)
KR (2) KR20140034861A (enExample)
CN (3) CN106946886A (enExample)
AR (1) AR089554A1 (enExample)
AU (2) AU2012275637B2 (enExample)
CA (2) CA2838738A1 (enExample)
MX (2) MX2013014892A (enExample)
RU (2) RU2598072C2 (enExample)
TW (1) TWI574965B (enExample)
WO (2) WO2013003249A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019500371A (ja) * 2015-12-25 2019-01-10 スーチュアン ハイスーク ファーマシューティカル カンパニー リミテッド 置換アミノピラン誘導体の結晶形
JP2019527708A (ja) * 2016-08-12 2019-10-03 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. Ｄｐｐ−ｉｖ長時間作用型阻害剤の結晶及びその塩
JP2019529480A (ja) * 2016-09-28 2019-10-17 アモーレパシフィック コーポレーションＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ （ｒ）−ｎ−［４−（１−アミノ−エチル）−２，６−ジフルオロ−フェニル］−メタンスルホンアミドの製造方法

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518266A (ja) * 2011-06-29 2014-07-28 メルク・シャープ・アンド・ドーム・コーポレーション ジペプチジルペプチダーゼ−ｉｖ阻害剤の新規結晶形
EP2814485A4 (en) 2012-02-17 2015-08-26 Merck Sharp & Dohme DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
EP2874626A4 (en) 2012-07-23 2016-03-23 Merck Sharp & Dohme TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
EP2874622A4 (en) 2012-07-23 2015-12-30 Merck Sharp & Dohme TREATMENT OF DIABETES WITH DIPEPTIDYLPEPTIDASE IV INHIBITORS
TWI500613B (zh) 2012-10-17 2015-09-21 Cadila Healthcare Ltd 新穎之雜環化合物
EP3038465B1 (en) 2013-08-30 2021-10-06 Merck Sharp & Dohme Corp. Oral pharmaceutical formulation of omarigliptin
ES2587585T3 (es) * 2014-03-20 2016-10-25 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Procedimiento para la preparación de intermedios clave de omarigliptina
CN105037367A (zh) * 2014-04-18 2015-11-11 四川海思科制药有限公司 氨基六元环类衍生物及其在医药上的应用
CN105085528A (zh) * 2014-05-15 2015-11-25 成都贝斯凯瑞生物科技有限公司 作为二肽基肽酶-iv抑制剂的氨基四氢吡喃衍生物
JP6574474B2 (ja) * 2014-07-21 2019-09-11 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． キラルジペプチジルペプチダーゼ−ｉｖ阻害剤の製造方法
WO2016015596A1 (en) * 2014-07-29 2016-02-04 Sunshine Lake Pharma Co., Ltd. Process for preparing 2, 3-disubstituted-5-oxopyran compound
CN106316888B (zh) * 2015-06-29 2018-05-18 深圳翰宇药业股份有限公司 一种手性氨基吡喃酮类化合物的合成方法
WO2017032705A1 (en) 2015-08-25 2017-03-02 Sandoz Ag Crystalline form of omarigliptin
CN105130995B (zh) * 2015-09-09 2017-08-11 杭州成邦医药科技有限公司 吡咯酮类化合物及其制备方法和应用
WO2017081590A1 (en) * 2015-11-09 2017-05-18 Sun Pharmaceutical Industries Limited Process for the preparation of omarigliptin
CN105348286B (zh) * 2015-11-25 2018-12-18 中山奕安泰医药科技有限公司 一种2-甲基磺酰基-2,4,5,6-四氢吡咯[3，4-c]吡唑苯磺酸盐的制备方法
WO2017093209A1 (en) 2015-12-03 2017-06-08 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Process for preparing aminotetrahydropyrans
CN105399744B (zh) * 2015-12-17 2017-07-18 黄燕鸽 一种奥格列汀的合成方法
EP3181565A1 (en) 2015-12-18 2017-06-21 Sandoz Ag Crystalline omarigliptin salts
CN106928228B (zh) * 2015-12-29 2019-08-30 杭州普晒医药科技有限公司 奥格列汀盐及其晶型、它们的制备方法和药物组合物
CN107652291B (zh) * 2016-07-26 2020-07-14 中国科学院上海药物研究所 一种制备手性四氢吡喃衍生物的方法
CN107793389B (zh) * 2016-09-05 2021-06-29 中国科学院上海药物研究所 手性四氢吡喃衍生物及其制备与用途
CN106674227B (zh) * 2016-12-06 2019-03-19 上海博志研新药物技术有限公司 一种奥格列汀及其中间体的制备方法
EP3335703A1 (en) 2016-12-16 2018-06-20 Hexal AG Pharmaceutical composition comprising omarigliptin
EP3335704A1 (en) 2016-12-16 2018-06-20 Hexal AG Pharmaceutical composition comprising omarigliptin
EP3335701A1 (en) 2016-12-16 2018-06-20 Hexal AG Pharmaceutical composition comprising omarigliptin
AR111295A1 (es) 2017-03-20 2019-06-26 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr)
US20200129485A1 (en) 2018-09-19 2020-04-30 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
CN113831266B (zh) * 2019-01-22 2024-04-05 河南医学高等专科学校 1-(2,5-二氟苯基)-1-氧代戊-4-炔-2-基氨基甲酸烷基酯的合成
CN110453177A (zh) * 2019-08-06 2019-11-15 太仓碧奇新材料研发有限公司 一种柔性有机整流器的制备方法
MX2022003025A (es) 2019-09-19 2022-04-07 Forma Therapeutics Inc Activacion de la piruvato cinasa r.
CN111793071B (zh) * 2020-07-06 2021-06-04 四川凯科医药科技有限公司 奥格列汀的合成工艺
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010056708A1 (en) * 2008-11-13 2010-05-20 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP2016198829A (ja) * 2015-04-07 2016-12-01 株式会社マキタ 打撃工具

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041442A (en) * 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
AU726361B2 (en) * 1997-03-21 2000-11-02 Du Pont Pharmaceuticals Company Method of making arylamino triazolopyridines
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CN1243707C (zh) 2000-09-14 2006-03-01 国家海洋局第一海洋研究所 共轭亚油酸的制造方法
EP1385508B1 (en) 2001-03-27 2008-05-21 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CA2450475A1 (en) 2001-06-20 2003-01-03 Linda Brockunier Dipeptidyl peptidase inhibitors for the treatment of diabetes
AU2002344820B2 (en) 2001-06-20 2006-12-14 Merck & Co., Inc. Dipeptidyl peptidase inhibitors for the treatment of diabetes
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
CN1212303C (zh) 2001-12-31 2005-07-27 中国科学院新疆理化技术研究所 使用混合溶剂合成共轭亚油酸的方法
EP1490335B1 (en) 2002-03-25 2007-09-19 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004007468A1 (en) 2002-07-15 2004-01-22 Merck & Co., Inc. Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes
WO2004032836A2 (en) 2002-10-07 2004-04-22 Merck & Co., Inc. Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors
HRP20050343A2 (en) 2002-10-18 2007-03-31 Merck & Co. Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP4413863B2 (ja) 2002-11-07 2010-02-10 メルク エンド カムパニー インコーポレーテッド 糖尿病の治療又は予防のためのジペチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体
JP2006510630A (ja) 2002-12-04 2006-03-30 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病を治療又は予防するためのジペプチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体
EP1583534A4 (en) 2002-12-20 2007-08-29 Merck & Co Inc 3-AMINO-4-PHENYLBUTANIC ACID DERIVATIVES AS DIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
CA2512546A1 (en) 2003-01-17 2004-08-05 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JP2006516573A (ja) 2003-01-31 2006-07-06 メルク　エンド　カムパニー　インコーポレーテッド 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体
US7603112B2 (en) * 2003-04-03 2009-10-13 Nokia Corporation System, mobile station, method and computer program product for managing context-related information
WO2004103276A2 (en) 2003-05-14 2004-12-02 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004110436A1 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
US7456204B2 (en) 2003-06-17 2008-11-25 Merck & Co., Inc. Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
JO2625B1 (en) * 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
CN1882551A (zh) 2003-07-31 2006-12-20 麦克公司 用作用于治疗或预防糖尿病的二肽基肽酶－iv酶抑制剂的六氢二氮杂吖庚因酮
CA2541212A1 (en) 2003-11-04 2005-05-19 Wallace T. Ashton Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2005108382A1 (en) 2004-05-04 2005-11-17 Merck & Co., Inc. 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2005116029A1 (en) 2004-05-18 2005-12-08 Merck & Co., Inc. Cyclohexylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
US7482336B2 (en) 2004-06-21 2009-01-27 Merck & Co., Inc. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
DE602005022320D1 (de) 2004-08-23 2010-08-26 Merck Sharp & Dohme Kondensierte triazolderivate als dipeptidylpeptidase-iv-hemmer zur behandlung bzw. prävention von diabetes
US7884104B2 (en) 2004-10-01 2011-02-08 Merck Sharp & Dohme Corp. Aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2006065826A2 (en) 2004-12-15 2006-06-22 Merck & Co., Inc. Process to chiral beta amino acid derivatives by asymmetric hydrogenation
AU2006206573B9 (en) 2005-01-19 2011-09-29 Merck Sharp & Dohme Corp. Bicyclic pyrimidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2006104997A2 (en) 2005-03-29 2006-10-05 Merck & Co., Inc. Tartaric acid salts of a dipeptidyl peptidase-iv inhibitor
US20090306037A1 (en) 2005-05-02 2009-12-10 Merck & Co., Inc. Combination of a Dipeptidyl Peptidase-IV Inhibitor and a Cannabinoid CB1 Receptor Antagonist for the Treatment of Diabetes and Obesity
US7906649B2 (en) 2005-05-25 2011-03-15 Merck Sharp & Dohme Corp. Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
EP1909776A2 (en) 2005-07-25 2008-04-16 Merck & Co., Inc. Dodecylsulfate salt of a dipeptidyl peptidase-iv inhibitor
US8017624B2 (en) 2005-08-26 2011-09-13 Merck Sharp & Dohme Corp. Fused aminopiperidines as dipeptidyi peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2007070434A2 (en) 2005-12-14 2007-06-21 Merck & Co., Inc. Fused aminopiperidines as dipeptidyl peptidase-4 inhibitors for the treatment or prevention of diabetes
WO2007078726A2 (en) 2005-12-16 2007-07-12 Merck & Co., Inc. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
JP5111398B2 (ja) 2006-01-25 2013-01-09 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖ阻害剤としてのアミノシクロヘキサン類
JP5161795B2 (ja) 2006-02-15 2013-03-13 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖインヒビターとしてのアミノテトラヒドロピラン
TW200806669A (en) 2006-03-28 2008-02-01 Merck & Co Inc Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
EP2019677B1 (en) 2006-05-16 2013-08-14 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2008060488A1 (en) 2006-11-14 2008-05-22 Merck & Co., Inc. Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
EP2190428A4 (en) 2007-08-21 2012-02-29 Merck Sharp & Dohme HETEROCYCLIC COMPOUNDS AS DIPEPTIDYLPEPTIDASE IV HEMMER FOR TREATMENT OR PREVENTION OF DIABETES
EP2228366B1 (de) 2009-03-12 2011-12-28 Archimica GmbH Verfahren zur Herstellung von 2-Amino-4-(halogenalkyl)pyridin-Derivaten durch Cyclisierung geeigneter Nitril-Vorstufen mit Stickstoff-Verbindungen
IN2012DN00721A (enExample) * 2009-09-02 2015-06-19 Merck Sharp & Dohme
US8716482B2 (en) * 2009-09-25 2014-05-06 Merck Sharp & Dohme Corp. Substituted aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment of diabetes
WO2011146358A1 (en) 2010-05-21 2011-11-24 Merck Sharp & Dohme Corp. Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
WO2012078448A1 (en) 2010-12-06 2012-06-14 Schering Corporation Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
EP2680851B1 (en) 2011-03-03 2016-08-17 Merck Sharp & Dohme Corp. Fused bicyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors
JP2014518266A (ja) 2011-06-29 2014-07-28 メルク・シャープ・アンド・ドーム・コーポレーション ジペプチジルペプチダーゼ−ｉｖ阻害剤の新規結晶形
EP2729468A4 (en) 2011-07-05 2015-03-18 Merck Sharp & Dohme Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010056708A1 (en) * 2008-11-13 2010-05-20 Merck Sharp & Dohme Corp. Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
JP2016198829A (ja) * 2015-04-07 2016-12-01 株式会社マキタ 打撃工具

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 283, JPN6015041512, 2004, pages 117 - 125, ISSN: 0003175738 *
実験化学講座（続）２ 分離と精製, JPN6012022299, 25 January 1967 (1967-01-25), pages 159 - 178, ISSN: 0003175737 *
新・薬剤学総論（改訂第３版）, vol. 株式会社南江堂, JPN6012025458, 10 April 1987 (1987-04-10), pages 111, ISSN: 0003175736 *
新製剤学, JPN6012022297, 25 April 1984 (1984-04-25), pages 102 - 103, ISSN: 0003175735 *
芦澤一英 他, 医薬品の多形現象と晶析の科学, JPN6015036200, 20 September 2002 (2002-09-20), JP, pages 3 - 16, ISSN: 0003175733 *
調剤学−基礎と応用−, JPN6012022295, 20 September 1977 (1977-09-20), pages 142 - 145, ISSN: 0003175734 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019500371A (ja) * 2015-12-25 2019-01-10 スーチュアン ハイスーク ファーマシューティカル カンパニー リミテッド 置換アミノピラン誘導体の結晶形
JP7014719B2 (ja) 2015-12-25 2022-02-01 スーチュアン ハイスーク ファーマシューティカル カンパニー リミテッド 置換アミノピラン誘導体の結晶形
JP2019527708A (ja) * 2016-08-12 2019-10-03 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッドChia Tai Tianqing Pharmaceutical Group Co., Ltd. Ｄｐｐ−ｉｖ長時間作用型阻害剤の結晶及びその塩
JP6997760B2 (ja) 2016-08-12 2022-01-18 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Ｄｐｐ－ｉｖ長時間作用型阻害剤の結晶及びその塩
JP2019529480A (ja) * 2016-09-28 2019-10-17 アモーレパシフィック コーポレーションＡｍｏｒｅｐａｃｉｆｉｃ Ｃｏｒｐｏｒａｔｉｏｎ （ｒ）−ｎ−［４−（１−アミノ−エチル）−２，６−ジフルオロ−フェニル］−メタンスルホンアミドの製造方法

Also Published As

Publication number Publication date
CN106946886A (zh) 2017-07-14
WO2013003250A1 (en) 2013-01-03
US9181262B2 (en) 2015-11-10
JP2014520802A (ja) 2014-08-25
RU2014102773A (ru) 2015-08-10
MX2013014892A (es) 2014-02-17
CN103702562A (zh) 2014-04-02
RU2598072C2 (ru) 2016-09-20
US20160024100A1 (en) 2016-01-28
CN103987388A (zh) 2014-08-13
US20140080884A1 (en) 2014-03-20
AU2012275638A1 (en) 2013-11-14
EP2726075A4 (en) 2014-11-19
EP2725905A1 (en) 2014-05-07
KR20140034861A (ko) 2014-03-20
US20140107346A1 (en) 2014-04-17
MX2013014891A (es) 2014-02-17
JP2017039752A (ja) 2017-02-23
JP2018115191A (ja) 2018-07-26
US20150099891A1 (en) 2015-04-09
RU2014102764A (ru) 2015-08-10
AU2012275637A1 (en) 2013-11-14
AR089554A1 (es) 2014-09-03
TWI574965B (zh) 2017-03-21
US9187488B2 (en) 2015-11-17
WO2013003249A1 (en) 2013-01-03
CA2838738A1 (en) 2013-01-03
US9527855B2 (en) 2016-12-27
EP2726075A1 (en) 2014-05-07
CA2838748A1 (en) 2013-01-03
AU2012275637B2 (en) 2016-05-12
MX341299B (es) 2016-08-11
KR20140034862A (ko) 2014-03-20
EP2725905A4 (en) 2014-11-26
US8895603B2 (en) 2014-11-25
JP5873554B2 (ja) 2016-03-01
TW201302759A (zh) 2013-01-16

Similar Documents

Publication Publication Date Title
US8895603B2 (en) Crystalline forms of a dipeptidyl peptidase-IV inhibitor
AU2004253889B2 (en) Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US7612072B2 (en) Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
US20080227786A1 (en) Novel Crystalline Salts of a Dipeptidyl Peptidase-IV Inhibitor
US20060287528A1 (en) Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
US20070021430A1 (en) Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2009014676A1 (en) Novel crystalline form of a dihydrochloride salt of a dipeptidyl peptidase-iv inhibitor
JP2012517990A (ja) 結晶質の多形性形態６３１
TW200404802A (en) Xanthine phosphodiesterase V inhibitor polymorphs
US20140336196A1 (en) Phosphoric acid salts of sitagliptin
JP2019500371A (ja) 置換アミノピラン誘導体の結晶形

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150402

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20151015

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161007

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20161024

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20161209